Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Invested Capital: 2016-2025

Historic Invested Capital for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $255.1 million.

  • Organogenesis Holdings' Invested Capital fell 10.33% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 10.33%. This contributed to the annual value of $262.9 million for FY2024, which is 7.48% down from last year.
  • Per Organogenesis Holdings' latest filing, its Invested Capital stood at $255.1 million for Q3 2025, which was up 9.38% from $233.2 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Invested Capital peaked at $315.4 million during Q4 2021, and registered a low of $227.3 million during Q1 2021.
  • Over the past 3 years, Organogenesis Holdings' median Invested Capital value was $269.3 million (recorded in 2024), while the average stood at $267.6 million.
  • In the last 5 years, Organogenesis Holdings' Invested Capital soared by 84.25% in 2021 and then fell by 14.73% in 2023.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Invested Capital stood at $315.4 million in 2021, then declined by 14.33% to $270.2 million in 2022, then grew by 5.16% to $284.1 million in 2023, then fell by 7.48% to $262.9 million in 2024, then declined by 10.33% to $255.1 million in 2025.
  • Its Invested Capital stands at $255.1 million for Q3 2025, versus $233.2 million for Q2 2025 and $242.9 million for Q1 2025.